PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF) - John Mascarenhas; Claire Harrison; Jean-Jacques Kiladjian; Katja Sockel; Alessandro Vannucchi; Tymara Berry; Denise Redding; Laurie Sherman; Souria Dougherty; Lixian Peng; Libo Sun; Fei Huang; et al. (HemaSphere, 2023)